NABsys Expands Leadership Team with Appointment of Stan Rose to Board of Directors

PROVIDENCE, R.I.--(BUSINESS WIRE)--NABsys Inc. announced today that industry veteran and serial entrepreneur, Stan Rose, Ph.D., has been appointed to the company’s board of directors. Dr. Rose is the most recent addition to the leadership team at NABsys, which recently raised $4 million in venture capital to further develop its proprietary electronic, solid-state DNA sequencing platform.

“The inherent power of electronic detection, combined with solid-state fabrication, provides a viable approach to address the capacity, throughput and performance issues that are currently barriers to widespread adoption.”

“Stan is an accomplished scientist and a proven industry leader who brings a successful track record of founding and growing genomics businesses,” said Barrett Bready, M.D., president and CEO of NABsys Inc. “His insights and experiences will help shape our commercialization strategy and guide us in our quest to deliver sequencing technology capable of the throughput and accuracy required to elucidate the genetic basis of complex disease and, ultimately, guide clinical care.”

“NABsys is developing a new approach to whole-genome DNA sequencing,” said Dr. Rose. “The inherent power of electronic detection, combined with solid-state fabrication, provides a viable approach to address the capacity, throughput and performance issues that are currently barriers to widespread adoption.”

Dr. Rose is president of Rose Ventures Inc., a firm that provides consulting and direction in the life science research products space, and manages a portfolio of public and private equity investments. Dr. Rose served as CEO of NimbleGen Systems, a microarray company that was acquired by Roche in 2007. He also co-founded and helped grow Genetic Microsystems, a microarray instruments company that was acquired by Affymetrix in 2000. Prior to that, Dr. Rose led the polymerase chain reaction (PCR) business for Perkin-Elmer and Applied Biosystems during its most dynamic growth phase in the 1990s. Dr. Rose holds a B.A. from Cornell University and Ph.D. from the Massachusetts Institute of Technology.

NABsys Vice President of Research and Development, John Oliver, Ph.D., will be presenting the company’s electronic, solid-state sequencing platform during Cambridge Healthtech Institute's Third Annual Exploring Next Generation Sequencing Conference on September 22, 2009.

About NABsys:

NABsys is a life sciences company working at the intersection of physics, biology, and computer science to develop its proprietary electronic, solid-state DNA sequencing platform. NABsys is one of five companies to receive a “$1000 Genome” award from the National Human Genome Research Institute of the National Institutes of Health. For more information about NABsys, please visit the company’s website at www.nabsys.com.

NOTE: NABsys and the NABsys logo are registered trademarks owned or used by NABsys Inc.